News

Understanding Medicinal Cannabis: How It Interacts with Your Body

Breaking Down the Science Behind Medicinal Cannabis

Medicinal cannabis has been gaining recognition worldwide as a therapeutic option for a variety of conditions. But how does it actually work in the body?

If you’re new to plant-based healthcare or simply looking to deepen your understanding, letโ€™s explore the fascinating ways medicinal cannabis interacts with our natural systems.

The Endocannabinoid System: Your Bodyโ€™s Built-In Balance Regulator

At the core of medicinal cannabisโ€™ effects is the endocannabinoid system (ECS)โ€”a complex network of receptors, enzymes, and naturally occurring cannabinoids (endocannabinoids) that help regulate balance in the bodyยน.

The ECS plays a crucial role in managing key functions, including:

  • Mood โ€“ Influences emotional regulation and stress responseยฒ.
  • Sleepย  โ€“ Helps maintain sleep cyclesยณ.
  • Pain Perceptionย  โ€“ Modulates pain signals throughout the nervous systemโด.
  • Immune Responseย  โ€“ Plays a role in inflammation controlโต.
  • Appetite & Digestionย  โ€“ Affects hunger signals and metabolismโถ.

Your body naturally produces endocannabinoids (such as anandamide and 2-AG) to keep these functions in check. However, when this system becomes imbalanced due to stress, illness, or other factors, external cannabinoidsโ€”such as those found in medicinal cannabisโ€”can help restore equilibriumโท.

How Medicinal Cannabis Interacts with the ECS

Medicinal cannabis contains phytocannabinoidsโ€”plant-derived compounds like THC (tetrahydrocannabinol) and CBD (cannabidiol)โ€”which mimic the function of endocannabinoids, binding to receptors in the ECS to regulate physiological processesโธ.

Two Main Receptors in the ECS

CB1 Receptors โ€“ Primarily found in the brain and central nervous system, CB1 receptors influence mood, memory, coordination, and pain perceptionโน. THC binds directly to these receptors, which is why it has psychoactive effects. However, in medicinal doses, THC is used to support pain relief, appetite stimulation, and relaxation without excessive intoxicationยนโฐ.

CB2 Receptors โ€“ Mostly found in the immune system and peripheral organs, CB2 receptors play a role in inflammation regulation, immune function, and overall body recoveryยนยน. CBD interacts with these receptors indirectly, helping to modulate pain and inflammation without the psychoactive effects of THCยนยฒ.

THC vs. CBD: Whatโ€™s the Difference?

While both compounds come from the same plant, THC and CBD work differently within the body:

THC: Binds directly to CB1 receptors, offering pain relief and relaxation but also producing psychoactive effects at higher dosesยนยณ.

CBD: Does not bind strongly to CB1 or CB2 receptors but modulates their activity, helping to reduce inflammation, ease anxiety, and support overall wellnessยนโด.

CBD is also known to reduce some of the unwanted effects of THC, such as paranoia or dizziness, which is why balanced formulations containing both compounds are often recommendedยนโต.

Not About โ€œGetting Highโ€ – Itโ€™s About Balance

One of the most common misconceptions about medicinal cannabis is that its primary effect is intoxication. The truth is, medicinal cannabis is prescribed to restore balance, not to create a recreational experienceยนโถ.

Because ECS dysfunction is linked to conditions like chronic pain, anxiety, PTSD, insomnia, and autoimmune diseases, cannabinoids can serve as a natural tool to help regulate these systemsยนโท. When used under medical supervision, patients often experience relief without impairmentยนโธ.

Why Do Effects Vary Between Individuals?

Each personโ€™s endocannabinoid system is unique, meaning that medicinal cannabis can affect individuals differently. Factors that influence response include:

Genetics โ€“ Some people naturally produce more endocannabinoids than othersยนโน.
Metabolism โ€“ The speed at which your body processes cannabinoids can impact how long effects lastยฒโฐ.
Dosage & Delivery Method โ€“ The way cannabis is taken (inhalation, oils, capsules) affects onset time and durationยฒยน.
Tolerance & Sensitivity โ€“ Those new to medicinal cannabis may respond differently than long-term patientsยฒยฒ.

This is why personalised treatment plans are keyโ€”starting with low doses and adjusting as needed allows for the best therapeutic outcomeยฒยณ.

A Science-Backed Approach to Wellness

Research on medicinal cannabis is continually evolving, but existing peer-reviewed studies suggest that cannabinoids can support:

๐Ÿ”น Chronic pain relief (including neuropathic pain and arthritis)ยฒโด
๐Ÿ”น Better sleep quality for those with insomnia or disrupted sleep cyclesยฒโต
๐Ÿ”น Reduced inflammation in conditions like Crohnโ€™s disease and multiple sclerosisยฒโถ
๐Ÿ”น Anxiety and stress management without significant side effectsยฒโท
๐Ÿ”น Nausea control for chemotherapy patientsยฒโธ

Final Thoughts: Finding the Right Support

Medicinal cannabis is a natural yet science-backed treatment option, working with your body’s own systems to restore balance. Whether youโ€™re exploring plant-based healthcare for the first time or refining your treatment plan, having the right guidance is essential.

Have questions? Our experienced medical team is here to help. Book a consultation today and explore how medicinal cannabis could fit into your wellness journey.

References (Peer-Reviewed Studies)

  1. Zou, S., & Kumar, U. (2018). Cannabinoid receptors and the endocannabinoid system: Signaling and function in the central nervous system. International Journal of Molecular Sciences, 19(3), 833.
  2. Lutz, B. (2020). The endocannabinoid system and emotional processing. European Neuropsychopharmacology, 30(2), 65-81.
  3. Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current Psychiatry Reports, 19(4), 23.
  4. Starowicz, K., & Finn, D. P. (2017). Cannabinoids and pain: Sites and mechanisms of action. Advances in Pharmacology, 80, 437-475.
  5. Klein, T. W. (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology, 5(5), 400-411.
  6. Di Marzo, V., & Matias, I. (2005). Endocannabinoid control of food intake and energy balance. Nature Neuroscience, 8(5), 585-589.
  7. Russo, E. B. (2016). Beyond cannabis: Plants and the endocannabinoid system. Trends in Pharmacological Sciences, 37(7), 594-606.
  8. Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: ฮ”9-tetrahydrocannabinol, cannabidiol, and ฮ”9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215.
  9. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., … & Ueda, N. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews, 54(2), 161-202.
  10. Aizpurua-Olaizola, O., Soydaner, U., ร–ztรผrk, E., Schibano, D., Simsir, Y., Navarro, P., … & Usobiaga, A. (2016). Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. Journal of Natural Products, 79(2), 324-331.
  11. Turcotte, C., Blanchet, M. R., Laviolette, M., & Flamand, N. (2016). The CB2 receptor and its role as a regulator of inflammation. Cellular and Molecular Life Sciences, 73(23), 4449-4470.
  12. Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., … & Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & Therapeutics, 175, 133-150.
  13. Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770-1804.
  14. Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825-836.
  15. Zuardi, A. W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Brazilian Journal of Psychiatry, 30(3), 271-280.
  16. Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219-2227.
  17. Atakan, Z. (2012). Cannabis, a complex plant: different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241-254.
  18. Ware, M. A., Wang, T., Shapiro, S., Collet, J. P., & COMPASS study team. (2015). Cannabis for the management of pain: Assessment of safety study (COMPASS). The Journal of Pain, 16(12), 1233-1242.
  19. Manzanares, J., Julian, M. D., & Carrascosa, A. (2006). Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Current Neuropharmacology, 4(3), 239-257.
  20. Hindocha, C., Freeman, T. P., Schafer, G., Gardener, C., Das, R. K., Morgan, C. J., & Curran, H. V. (2015). Acute effects of delta-9-tetrahydrocannabinol, cannabidiol, and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users. European Neuropsychopharmacology, 25(3), 325-334.
  21. Bridgeman, M. B., & Abazia, D. T. (2017). Medicinal cannabis: History, pharmacology, and implications for the acute care setting. Pharmacy and Therapeutics, 42(3), 180-188.
  22. Lucas, P. (2012). Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. Journal of Psychoactive Drugs, 44(2), 125-133.
  23. McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015). Are cannabidiol and ฮ”9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 172(3), 737-753.
  24. Baron, E. P. (2018). Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis and benefits in migraine, headache, and pain: An update on current evidence and cannabis science. Headache: The Journal of Head and Face Pain, 58(7), 1139-1186.
  25. Tashkin, D. P. (2013). Effects of marijuana smoking on the lung. Annals of the American Thoracic Society, 10(3), 239-247.
  26. Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., … & Cilio, M. R. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011-2020.
  27. Crippa, J. A. S., Guimarรฃes, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Frontiers in Immunology, 9, 2009.
  28. Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163(7), 1411-1422.

ย 

Related Posts: